权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma

项目 2：使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法

基本信息

批准号：
10683757
负责人：
HASSANE M ZAROUR
金额：
$ 36.97万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10683757
关键词：
Adjuvant Adverse event Agonist Antibodies Antigen Presentation B-Lymphocytes Binding Biological CD8-Positive T-Lymphocytes CD8B1 gene CTLA4 blockade Cancer Vaccines Cell Death Cell Maturation Cells Cellular Indexing of Transcriptomes and Epitopes by Sequencing Clinical Combination immunotherapy Cytosine Defect Dendritic Cells Dendritic cell activation Epitope spreading Epitopes Evaluable Disease Experimental Models Flow Cytometry Frequencies Guanosine Human Immune response Immunotherapy Interferon Type I Interferon alpha Interferons Mediating Melanoma Cell Metastatic Melanoma Methylation Monoclonal Antibodies Mus Necrosis Neoadjuvant Therapy Nivolumab PD-1 blockade Pathologic Patients Peptide Vaccines Phase II/III Clinical Trial Positron-Emission Tomography Production Progression-Free Survivals Property RIPK3 gene Randomized Refractory Resectable Resistance Serious Adverse Event Signal Transduction Skin Cancer Solid Neoplasm Survival Rate T cell receptor repertoire sequencing T cell response T-Lymphocyte TLR9 gene Therapeutic Toxic effect Tumor Antigens Tumor Expansion Tumor Immunity Tumor Promotion Vaccines anti-CTLA4 anti-PD-1 anti-PD1 antibodies antigen-specific T cells beta-2 Microglobulin cancer infiltrating T cells clinical efficacy combinatorial digital exhaust first-in-human high risk immune checkpoint blockade immunogenicity improved in vivo melanoma melanoma-associated antigen neoantigens novel programmed cell death protein 1 programs recruit resistance mechanism response spectrograph transcriptomics tumor tumor microenvironment

项目摘要

PROJECT SUMMARY ABSTRACT: Project 2 Immunotherapy with anti-PD1 monoclonal antibodies (mAbs) is associated with improved response and survival rates in multiple solid tumors, including melanoma1. Anti-PD1 mAbs (anti-PD1) produces durable clinical responses in 33-40% of melanoma patients with minimal toxicity. While dual anti-PD1/anti-CTLA4 blockade produces higher response rates (58%) and 5-year PFS (36%), this is associated with 55% grade 3/4 adverse events. Therefore, there is a critical need for novel combinatorial immunotherapy to improve the efficacy of anti-PD1 while mitigating the rate of serious adverse events in advanced melanoma. One major barrier limiting the efficacy of anti-PD1 is the lack of spontaneous tumor-infiltrating T cells (TILs) and defective IFNa production in tumor microenvironment (TME) in so-called “cold” or non-inflamed tumors. One promising therapeutic approach to overcome this hurdle is via toll-like receptor 9 (TLR9) agonists. TLR9 is predominantly expressed by plasmacytoid dendritic cells (pDCs) and B cells and binds to agonists including unmethylated cytosine guanosine oligodinucleotides (CpG). We have recently performed the first-in-human trial of neoadjuvant intratumoral CMP, a novel type A CpG, and Nivolumab in PD1-naïve high-risk resectable melanoma (NCT03618641). In 30 evaluable melanoma patients, we have observed 60% major pathologic responses with increased CD8+ TILs and peritumoral CD303+ pDCs in injected tumors, and higher frequency circulating PD1+Ki67+CD8+ T cells in responders. Therapy with intratumoral CMP and Nivolumab (CMP/Nivolumab) has also shown clinical efficacy in PD1 refractory melanoma with responses in non-injected tumors, supporting the occurrence of systemic antitumor immunity beyond the injected tumors. To further our understanding of the mechanisms of responses or resistance to CMP/Nivolumab in injected and non-injected tumors, we will take advantage of a substudy of 60 melanoma patients included in the randomized phase II/III clinical trial evaluating CMP/nivolumab vs. nivolumab in PD1 naïve metastatic melanoma with accessible tumors for intratumoral CMP. Based on our preliminary findings, we will investigate whether CMP/Nivolumab :1) increases pDC activation and recruitment into injected tumors to promote CD8+TIL expansion and functions in injected and non-injected tumors; 2) induces melanoma cell death, primes potent neoepitope-specific CD8+T cells in injected tumors, and epitope spreading to melanoma-associated antigens; and 3) fails to induce potent T cell responses because of melanoma cell-extrinsic or melanoma cell-intrinsic mechanisms. Collectively, the findings in this application will improve our understanding of the mechanisms of response and resistance to CMP/Nivolumab in melanoma. They will further support novel combinatorial immunotherapies to further enhance the immunogenicity and clinical activity of CMP/Nivolumab in injected and non-injected tumors of advanced melanoma.

项目摘要：项目二